Results 261 to 270 of about 6,764,527 (311)
Some of the next articles are maybe not open access.
Zhongguo shi yan xue ye xue za zhi, 2022
To construct a mouse model of Glanzmann's thrombasthenia (GT) with ITGA2B c.2659 C>T (p.Q887X) nonsense mutation by CRISPR/Cas9 technology, and then further explore the expression and function of glycoprotein αIIbβ3 on the surface of platelet membrane.The donor oligonucleotide and gRNA vector were designed and synthesized according to the ITGA2B gene ...
Fei, Yang +8 more
openaire +1 more source
To construct a mouse model of Glanzmann's thrombasthenia (GT) with ITGA2B c.2659 C>T (p.Q887X) nonsense mutation by CRISPR/Cas9 technology, and then further explore the expression and function of glycoprotein αIIbβ3 on the surface of platelet membrane.The donor oligonucleotide and gRNA vector were designed and synthesized according to the ITGA2B gene ...
Fei, Yang +8 more
openaire +1 more source
International Journal of Circuit Theory and Applications
AbstractThe excessive power usage in modern digital equipment is triggered by memory arrays, mainly including Static Random‐Access Memory (SRAM) chips. Many scientists are working to create an SRAM cell that is fast, highly stable, and uses little power.
Pushkar Praveen, Rakesh Kumar Singh
openaire +1 more source
AbstractThe excessive power usage in modern digital equipment is triggered by memory arrays, mainly including Static Random‐Access Memory (SRAM) chips. Many scientists are working to create an SRAM cell that is fast, highly stable, and uses little power.
Pushkar Praveen, Rakesh Kumar Singh
openaire +1 more source
IEEE Transactions on Ultrasonics, Ferroelectrics and Frequency Control, 2016
P. Krehlik +4 more
semanticscholar +1 more source
P. Krehlik +4 more
semanticscholar +1 more source
2014
Somewhat surprisingly, the first active cancer immunotherapy was approved with sipuleucel-T, an autologous cell therapy, in castrate-resistant prostate carcinoma rather than in melanoma, the test disease for many immunotherapies in the past. Sipuleucel-T is followed suit by other vaccines against prostate carcinoma that are now on advanced clinical ...
openaire +1 more source
Somewhat surprisingly, the first active cancer immunotherapy was approved with sipuleucel-T, an autologous cell therapy, in castrate-resistant prostate carcinoma rather than in melanoma, the test disease for many immunotherapies in the past. Sipuleucel-T is followed suit by other vaccines against prostate carcinoma that are now on advanced clinical ...
openaire +1 more source
Selective Ex Vivo T-Cell Expansion Using Next Generation Expansion DynabeadsTM Technology
Cytotherapy, 2016H. Almåsbak +6 more
openaire +1 more source
Radiotheranostics in oncology: Making precision medicine possible
Ca-A Cancer Journal for Clinicians, 2023Eric Aboagye
exaly